EFEMP1 and lung carcinoma: In addition to fibulin-5 silencing, several other aberrations in lung cancer can lead to activation of the Wnt pathway, such as overexpression of Wnt ligands [20], downregulation of Wnt antagonists such as dickkopf 3 [10], and loss of fibulin-3 expression [12].